Compare GSK plc (GSK) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares MSCI China ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares MSCI China ETF trades at $52.55 (market cap $5.94B). The key difference: GSK plc is far larger — about 15.5× iShares MSCI China ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares MSCI China ETF for 63 Days on average.
| GSK | MCHI | |
|---|---|---|
Market Cap | $91.88B | $5.94B |
Volume | 7,730,529 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $65.59 |
52-Week Low | $43.24 | $50.48 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
MCHI trades at $51.36, down 0.54% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights trade tensions ahead of U.S.-China talks, though corporate profits surged 26% in Q2. Technical indicators show oversold conditions with RSI at 25.44 suggesting potential for near-term bounce.
The outlook remains cautious given China's macroeconomic pressures and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations versus U.S. indices. Key risks include potential export controls, protectionism threats, and China's reliance on infrastructure spending rather than broad stimulus to support growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
